The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
A binary Xpovio catalyst is set for March.
BeOne terminates a MUC1-targeting project.
